{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:13:35Z","timestamp":1794395615873,"version":"4.9.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Complementary Therapies in Medicine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ctim.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T20:16:06Z","timestamp":1503778566000},"page":"170-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1016","volume":"34","author":[{"given":"Victoria P.","family":"da Rovare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel P.A.","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme D.A.","family":"Jardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus L.","family":"Beraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariel O.","family":"Gameiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Jos\u00e9","family":"Luvizutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Paula-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Esteves Afonso","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane Dias","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"El Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctim.2017.08.010_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1017\/cjn.2015.271","article-title":"Spasticity health literacy among canadian family phisicians","volume":"42","author":"Goldstein","year":"2015","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.ctim.2017.08.010_bib0010","first-page":"847","article-title":"Cannabinoids in the management of spasticity associated with multiple sclerosis","volume":"4","author":"Malfitano","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.ctim.2017.08.010_bib0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.sc.3101757","article-title":"Spasticity after spinal cord injury","volume":"43","author":"Adams","year":"2005","journal-title":"Spinal Cord"},{"key":"10.1016\/j.ctim.2017.08.010_bib0020","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/S0003-9993(99)90329-5","article-title":"Spasticity after traumatic spinal cord injury: nature, severity, and location","volume":"80","author":"Sk\u00f6ld","year":"1999","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.ctim.2017.08.010_bib0025","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1590\/S0004-282X1998000500025","article-title":"Treatment of spasticity: an update","volume":"56","author":"Teive","year":"1998","journal-title":"Arq Neuro-Psiquiatr"},{"key":"10.1016\/j.ctim.2017.08.010_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-013-1277-1","article-title":"Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas","volume":"116","author":"Rocha","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0035","unstructured":"David Potter, The propagation, characterisation and optimisation of cannabis sativa L as a phytopharmaceutical. JP MlBiol CBiol FLS CMIOSH."},{"key":"10.1016\/j.ctim.2017.08.010_bib0040","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ctim.2017.08.010_bib0045","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1001\/jama.2015.6199","article-title":"Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review","volume":"313","author":"Hill","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ctim.2017.08.010_bib0050","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1016\/j.ctim.2017.08.010_bib0055","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ctim.2017.08.010_bib0060","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: quality of reporting of meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ctim.2017.08.010_bib0065","series-title":"Modification of Cochrane Tool to Assess Risk of Bias in Randomized Trials","author":"Guyatt","year":"2017"},{"key":"10.1016\/j.ctim.2017.08.010_bib0070","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ctim.2017.08.010_bib0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0080","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0085","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE working group. GRADE guidelines: 7. Rating the quality of evidence-inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0090","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence-indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.ctim.2017.08.010_bib0095","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence-publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0100","series-title":"The Cochrane Collaboration. Review Manager (RevMan). 5.3","author":"The Nordic Cochrane Centre","year":"2011"},{"key":"10.1016\/j.ctim.2017.08.010_bib0105","series-title":"An Investigation of Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients","year":"2017"},{"key":"10.1016\/j.ctim.2017.08.010_bib0110","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1503\/cmaj.110837","article-title":"Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial","volume":"184","author":"Corey-Bloom","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.ctim.2017.08.010_bib0115","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.apmr.2009.12.025","article-title":"A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury","volume":"91","author":"Pooyania","year":"2010","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.ctim.2017.08.010_bib0120","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejpain.2008.05.014","article-title":"Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis","volume":"13","author":"Conte","year":"2009","journal-title":"Eur J Pain"},{"key":"10.1016\/j.ctim.2017.08.010_bib0125","series-title":"Randomized Double Blind Cross over Study for Nabilone in Spasticity in Spinal Cord Injury Persons","year":"2017"},{"key":"10.1016\/j.ctim.2017.08.010_bib0130","series-title":"Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis","year":"2017"},{"key":"10.1016\/j.ctim.2017.08.010_bib0135","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00415-006-0218-8","article-title":"Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial","volume":"253","author":"Wissel","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","article-title":"Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study","volume":"10","author":"Vaney","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.ctim.2017.08.010_bib0145","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","article-title":"Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients","volume":"10","author":"Wade","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.ctim.2017.08.010_bib0150","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.58.9.1404","article-title":"Safety, tolerability, and efficacy of orally administered cannabinoids in MS","volume":"58","author":"Killestein","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ctim.2017.08.010_bib0155","series-title":"Sativex Versus Placebo when Added to Existing Treatment for Central Neuropathic Pain in M.S.","year":"2017"},{"key":"10.1016\/j.ctim.2017.08.010_bib0160","series-title":"A Study of Sativex\u00ae for Relief of Spasticity in Subjects with Multiple Sclerosis","year":"2017"},{"key":"10.1016\/j.ctim.2017.08.010_bib0165","series-title":"A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis","year":"2017"},{"key":"10.1016\/j.ctim.2017.08.010_bib0170","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s00415-012-6739-4","article-title":"A double-blind, randomized, placebo-controlled, parallel-group study of THC\/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis","volume":"260","author":"Langford","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0175","series-title":"A Study of Cannabis Based Medicine Extracts and Placebo in Patients with Pain Due to Spinal Cord Injury","year":"2017"},{"key":"10.1016\/j.ctim.2017.08.010_bib0180","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/jnnp-2012-302468","article-title":"Multiple sclerosis and extract of cannabis: results of the MUSEC trial","volume":"83","author":"Zajicek","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ctim.2017.08.010_bib0185","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(\u00ae)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1179\/016164109X12590518685660","article-title":"A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis","volume":"32","author":"Collin","year":"2010","journal-title":"Neurol Res"},{"key":"10.1016\/j.ctim.2017.08.010_bib0195","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1177\/1352458510378020","article-title":"Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis","volume":"16","author":"Kavia","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.ctim.2017.08.010_bib0200","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ctim.2017.08.010_bib0205","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","article-title":"The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)","volume":"17","author":"Freeman","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.ctim.2017.08.010_bib0210","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","article-title":"Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up","volume":"76","author":"Zajicek","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"362","key":"10.1016\/j.ctim.2017.08.010_bib0215","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial","volume":"8","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ctim.2017.08.010_bib0220","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/0269215503cr581oa","article-title":"A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms","volume":"17","author":"Wade","year":"2003","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.ctim.2017.08.010_bib0225","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/jnnp-2015-312591","article-title":"Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity","volume":"87","author":"Patti","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ctim.2017.08.010_bib0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1756285615612659","article-title":"Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis","volume":"9","author":"Zettl","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.ctim.2017.08.010_bib0235","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.pain.2004.09.013","article-title":"Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial","volume":"112","author":"Berman","year":"2004","journal-title":"Pain"}],"container-title":["Complementary Therapies in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0965229917304466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0965229917304466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:08:21Z","timestamp":1760807301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0965229917304466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":47,"alternative-id":["S0965229917304466"],"URL":"https:\/\/doi.org\/10.1016\/j.ctim.2017.08.010","relation":{},"ISSN":["0965-2299"],"issn-type":[{"value":"0965-2299","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Complementary Therapies in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctim.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}